GH Research shares surge 12.63% premarket as Wall Street analysts project potential 130.59% rally.

GH Research PLC (GHRS) surged 12.63% in premarket trading, driven by recent positive developments in its psychedelic therapy pipeline. The company announced a 73% remission rate in its Phase 2b depression trial for GH001, signaling strong clinical efficacy. Additionally, GH Research submitted its response to the FDA’s IND hold ahead of schedule, addressing regulatory concerns and accelerating development timelines. Analysts from Wall Street, including Zacks, highlighted a potential 130.59% price target, citing momentum in psychedelic sector M&A and favorable business updates. These catalysts—robust trial data, regulatory progress, and analyst optimism—collectively fueled investor confidence, propelling the stock’s sharp premarket gain.